Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Floxuridine + Leronlimab |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Floxuridine | FUDR | 5 Fluorodeoxyuridine | ||
| Leronlimab | PRO140|PRO 140|anti-CCR5 antibody | Leronlimab is a monoclonal antibody that targets CCR5, which potentially induces killing of tumor cells expressing CCR5, inhibits invasion and metastasis, and reduces tumor burden (Cancer Res 2020;80(4 Suppl):Abstract nr PD4-04). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07842965 | Phase I | Leronlimab Floxuridine + Leronlimab | CCR5 Targeting Leronlimab in Combination With Hepatic Arterial Infusion Floxuridine and Systemic Therapy for the Treatment of Colorectal Cancer Liver Metastases, CHAMP Trial | Not yet recruiting | USA | 0 |